680 related articles for article (PubMed ID: 31030123)
1. Management of metastatic bladder cancer.
Nadal R; Bellmunt J
Cancer Treat Rev; 2019 Jun; 76():10-21. PubMed ID: 31030123
[TBL] [Abstract][Full Text] [Related]
2. Updates and novel treatments in urothelial carcinoma.
Hanna KS
J Oncol Pharm Pract; 2019 Apr; 25(3):648-656. PubMed ID: 30304985
[TBL] [Abstract][Full Text] [Related]
3. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
Bednova O; Leyton JV
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
[TBL] [Abstract][Full Text] [Related]
4. Erdafitinib for the treatment of metastatic bladder cancer.
Montazeri K; Bellmunt J
Expert Rev Clin Pharmacol; 2020 Jan; 13(1):1-6. PubMed ID: 31810398
[No Abstract] [Full Text] [Related]
5. Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma.
Inokuchi J; Eto M
Cancer Manag Res; 2019; 11():4519-4528. PubMed ID: 31191013
[TBL] [Abstract][Full Text] [Related]
6. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab in the treatment of advanced urothelial cancer.
Lundgren KT; Farina MS; Bellmunt J
Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
[TBL] [Abstract][Full Text] [Related]
8. Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
Hanna KS
Drugs; 2020 Jan; 80(1):1-7. PubMed ID: 31823332
[TBL] [Abstract][Full Text] [Related]
9. Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives.
Iacovelli R; Cicala CM; Ciccarese C; Sacco E; Racioppi M; Bassi PF; Tortora G
Urologia; 2023 Feb; 90(1):3-10. PubMed ID: 36537831
[TBL] [Abstract][Full Text] [Related]
10. Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy.
Chism DD
J Natl Compr Canc Netw; 2017 Oct; 15(10):1277-1284. PubMed ID: 28982752
[TBL] [Abstract][Full Text] [Related]
11. Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review.
Bantounou MA; Plascevic J; MacDonald L; Wong MC; O'Connell N; Galley HF
Curr Urol; 2023 Dec; 17(4):271-279. PubMed ID: 37994340
[TBL] [Abstract][Full Text] [Related]
12. Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options.
Koufopoulou M; Miranda PAP; Kazmierska P; Deshpande S; Gaitonde P
Cancer Treat Rev; 2020 Sep; 89():102072. PubMed ID: 32769039
[TBL] [Abstract][Full Text] [Related]
13. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
14. Current Therapy for Metastatic Urothelial Carcinoma.
Nadal R; Clara JA; Valderrama BP; Bellmunt J
Hematol Oncol Clin North Am; 2021 Jun; 35(3):469-493. PubMed ID: 33958146
[TBL] [Abstract][Full Text] [Related]
15. Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.
Grivas P; Agarwal N; Pal S; Kalebasty AR; Sridhar SS; Smith J; Devgan G; Sternberg CN; Bellmunt J
Cancer Treat Rev; 2021 Jun; 97():102187. PubMed ID: 33839438
[TBL] [Abstract][Full Text] [Related]
16. The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
Lavoie JM; Sridhar SS; Ong M; North S; Alimohamed N; McLeod D; Eigl BJ
Oncologist; 2021 Aug; 26(8):e1381-e1394. PubMed ID: 34028134
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
18. The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor.
Morales-Barrera R; Suárez C; González M; Valverde C; Serra E; Mateo J; Raventos C; Maldonado X; Morote J; Carles J
Cancer Treat Rev; 2020 Jun; 86():102000. PubMed ID: 32203842
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy and urothelial carcinoma: An overview and future prospectives.
Pierantoni F; Maruzzo M; Gardi M; Bezzon E; Gardiman MP; Porreca A; Basso U; Zagonel V
Crit Rev Oncol Hematol; 2019 Nov; 143():46-55. PubMed ID: 31476551
[TBL] [Abstract][Full Text] [Related]
20. Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options.
Park I; Lee JL
Korean J Intern Med; 2020 Jul; 35(4):834-853. PubMed ID: 32668516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]